Welcome to our dedicated page for Summit Therapeutics news (Ticker: SMMT), a resource for investors and traders seeking the latest updates and insights on Summit Therapeutics stock.
Summit Therapeutics Inc. develops oncology medicines led by ivonescimab, an investigational PD-1 / VEGF bispecific antibody in-licensed from Akeso. The company reports clinical and operational updates for ivonescimab programs in non-small cell lung cancer and colorectal cancer, including multiregional Phase III studies and data presentations from HARMONi trials.
Recurring Summit Therapeutics news also covers financial results, regulatory updates tied to the accepted Biologics License Application for ivonescimab in EGFR-mutated non-squamous NSCLC after tyrosine kinase inhibitor therapy, clinical trial collaborations, and equity-compensation actions under Nasdaq rules. Summit holds development and commercialization rights for ivonescimab across North America, South America, Europe, the Middle East, Africa, and Japan.
Summit Therapeutics (NASDAQ: SMMT) has announced a clinical trial collaboration with Pfizer (NYSE: PFE) to evaluate ivonescimab, a novel PD-1/VEGF bispecific antibody, in combination with Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings.
The collaboration aims to assess ivonescimab with several of Pfizer's vedotin-based ADCs in distinct solid tumor settings to determine safety profiles and potential anti-tumor activity. Summit will provide ivonescimab while Pfizer will conduct the studies, with both companies overseeing the trials. Both parties maintain their respective product rights.
The clinical trials are scheduled to begin in mid-2024, with further details to be announced later. The partnership focuses on developing novel mechanisms beyond current available treatments, particularly targeting non-small cell lung cancer and other solid tumors.
Summit Therapeutics (NASDAQ: SMMT) has announced it will host an earnings conference call to discuss its fourth quarter and full year 2024 financial results on Monday, February 24, 2025, before market opening. The company will also provide an operational update during the call, which is scheduled for 9:00am ET. The event will be accessible through a live webcast on Summit's website (www.smmttx.com), and an archived version will be made available afterward.
Summit Therapeutics (NASDAQ: SMMT) has announced the granting of inducement stock options to nine new employees. The awards consist of options to purchase up to 116,725 shares of common stock, with an exercise price of $19.08 per share, based on the closing price on February 11, 2025.
The options have a ten-year term and will vest in equal annual installments over a four-year period. These inducement awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by Summit's Compensation Committee from an equity incentive pool reserved on May 3, 2024.
Summit Therapeutics (NASDAQ: SMMT) has announced the granting of inducement stock options to nine new employees. The awards total 145,550 shares of common stock and were granted on January 10, 2025, with an exercise price of $17.85 per share, matching the closing price on the grant date.
The options have a ten-year term and will vest in equal annual installments over four years. These awards were granted from an equity incentive pool specifically reserved for new employee inducements, as approved by the Company's Compensation Committee on May 3, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
Summit Therapeutics (NASDAQ: SMMT) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for Monday, January 13, 2025, at 3:00 PM PT.
Chairman and CEO Robert W. Duggan and CEO & President Dr. Maky Zanganeh will deliver a corporate overview and provide updates on the company's progress, with particular focus on their innovative investigational bispecific antibody, ivonescimab.
The presentation will be accessible live through Summit's website (www.smmttx.com), with an archived version available for viewing after the event.
Summit Therapeutics (NASDAQ: SMMT) has announced the granting of inducement stock options to six new employees. The awards total 98,000 shares of common stock, with an exercise price of $17.97 per share, based on the closing price on December 10, 2024. These ten-year options, approved by the Company's Compensation Committee, will vest in equal annual installments over four years. The grants were made from a pre-approved equity incentive pool established on May 3, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
Summit Therapeutics (NASDAQ: SMMT) announced its participation in two major healthcare conferences in Miami. The company will present at the 7th Annual Evercore HealthCONx Conference on December 3, 2024, and Citi's 2024 Global Healthcare Conference on December 4, 2024, both at 8:45am ET.
The management team will conduct fireside chats focusing on the development of their investigational bispecific antibody, ivonescimab. Both presentations will be accessible live through Summit's website and will remain available in archived form afterward.
Summit Therapeutics (NASDAQ: SMMT) has granted inducement awards of stock options to 15 new employees. The options allow for the purchase of up to 227,600 shares of common stock at an exercise price of $18.31 per share, matching the closing price on November 15, 2024. These ten-year options will vest in equal annual installments over four years. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by the Company's Compensation Committee from an equity incentive pool reserved on May 3, 2024.
Summit Therapeutics (NASDAQ: SMMT) reported significant progress in Q3 2024, highlighted by their lead drug ivonescimab achieving a 49% reduction in disease progression or death compared to pembrolizumab in first-line PD-L1 positive advanced NSCLC. The company completed enrollment in the global Phase III HARMONi trial, received FDA Fast Track Designation, and plans to expand the HARMONi-3 trial to include non-squamous histology patients. Summit raised $235 million in private financing, ending Q3 with $487 million in cash. Financial results showed GAAP net loss of $56.3 million ($0.08 per share) and increased R&D expenses to $37.7 million, reflecting expanded clinical development activities.
Nuvectis Pharma (NASDAQ: NVCT) showcased promising results at the AACR-NCI-EORTC Symposium, where its drug candidate NXP900 demonstrated strong synergy with ALK inhibitors in resistant non-small cell lung cancer (NSCLC) cells. The drug effectively targets SRC/YES1 kinases, addressing resistance mechanisms in cancer treatment.
The company is also anticipating data updates from NXP800's Phase 1b study in platinum-resistant, ARID1a-mutated ovarian cancer. With a current market valuation of approximately $150 million, Nuvectis is positioning itself alongside industry players like Summit Therapeutics ($15B) and Nuvalent ($6.6B) in the precision oncology space.